Therapeutics
Heqet Therapeutics develops first-in-class non-coding RNA-based compounds to address highly unmet medical needs in acute myocardial infarction and other cardiovascular diseases.
A disruptive approach, to the heart of the disease
Heqet Therapeutics is a pre-clinical stage biotech company developing non-coding RNA-based therapies for cardiovascular diseases, with a particular emphasis on acute myocardial infarction.
The company originates from the pioneering research of Prof. Mauro Giacca, Professor of Cardiovascular Sciences and Head of the School of Cardiovascular and Metabolic Medicine & Sciences at King’s College London.
Our vision is to become the standard of care for myocardial infarction induced regeneration
Heqet Therapeutics pipeline compounds efficiently target multiple pathways via the upregulation of certain non-coding RNAs.
These include two factors in the Hippo pathway, the upstream inhibitory TAO kinase 1 (TAOK1) and the phospho-YAP E3 ubiquitin-ligase β-transducing repeat containing protein (β-TrCP)15, and the actin cytoskeleton regulatory protein cofilin-216.
The need to develop novel therapies for heart failure consequent to myocardial infarction is impelling
We’ll be happy to hear from you
Get in touch with Heqet Therapeutics to explore groundbreaking opportunities at the frontier of RNA-based cardiovascular therapies.
Key publications
Mauro Giacca
May 2019
Mauro Giacca
May 2019
